PLYX NASDAQ
Polaryx Therapeutics, Inc. Common Stock
1W: -5.2%
1M: -12.9%
3M: -8.5%
YTD: -94.8%
$1.91
+0.09 (+4.95%)
Weekly Expected Move ±5.0%
$2
$2
$2
$2
$2
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history. Altman Z'' -12.99.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$90.7M
52W Range1.755-48.91
Volume27,514
Avg Volume75,364
Beta-8.91
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAlex Yang
Employees11
SectorHealthcare
IndustryBiotechnology
IPO Date2026-02-02
Websitepolaryx.com
South Tower
Paramus, NJ 07652
US
Paramus, NJ 07652
US
(201) 940-7236
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Latest News
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
12 Health Care Stocks Moving In Friday's After-Market Session
Why Polaryx Therapeutics Stock Is Surging On Thursday?
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
Recent Insider Trades
No insider trades found